US20160175279A1 - Method of treating neurodegenerative disorders - Google Patents
Method of treating neurodegenerative disorders Download PDFInfo
- Publication number
- US20160175279A1 US20160175279A1 US14/902,190 US201414902190A US2016175279A1 US 20160175279 A1 US20160175279 A1 US 20160175279A1 US 201414902190 A US201414902190 A US 201414902190A US 2016175279 A1 US2016175279 A1 US 2016175279A1
- Authority
- US
- United States
- Prior art keywords
- body weight
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HFJPFYWFLJIQSM-QERFXVJSSA-N [H][C@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C Chemical compound [H][C@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C HFJPFYWFLJIQSM-QERFXVJSSA-N 0.000 description 3
- HFJPFYWFLJIQSM-NBKVVBEDSA-N [H][C@@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C Chemical compound [H][C@@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C HFJPFYWFLJIQSM-NBKVVBEDSA-N 0.000 description 2
- YLQMMTOEXSQLQR-NFHPCFQFSA-N C.[H][C@@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C.[H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C3[C@H](C)[C@@H]3OC(C=C)O[C@@H](C[C@H]4CC[C@]41OC(C)=O)[C@@]32C.[H][C@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C Chemical compound C.[H][C@@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C.[H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C3[C@H](C)[C@@H]3OC(C=C)O[C@@H](C[C@H]4CC[C@]41OC(C)=O)[C@@]32C.[H][C@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C YLQMMTOEXSQLQR-NFHPCFQFSA-N 0.000 description 1
- DGJYTVRYWAVFIE-AUYZMQIPSA-N [H][C@@]1(C=C)O[C@H]2C[C@H]3OC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C.[H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C3[C@H](C)[C@@H]3OC(C=C)O[C@@H](C[C@H]4CC[C@]41OC(C)=O)[C@@]32C.[H][C@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C Chemical compound [H][C@@]1(C=C)O[C@H]2C[C@H]3OC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C.[H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C3[C@H](C)[C@@H]3OC(C=C)O[C@@H](C[C@H]4CC[C@]41OC(C)=O)[C@@]32C.[H][C@]1(C=C)O[C@H]2C[C@H]3CC[C@@]3(OC(C)=O)[C@@]3([H])[C@H](OC(=O)C4=CC=CC=C4)[C@]4(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C4[C@H](C)[C@H](O1)[C@]23C DGJYTVRYWAVFIE-AUYZMQIPSA-N 0.000 description 1
- HFJPFYWFLJIQSM-NSJVPOEISA-N [H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C3[C@H](C)[C@@H]3OC(C=C)O[C@@H](C[C@H]4CC[C@]41OC(C)=O)[C@@]32C Chemical compound [H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(C(C)(C)O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C3[C@H](C)[C@@H]3OC(C=C)O[C@@H](C[C@H]4CC[C@]41OC(C)=O)[C@@]32C HFJPFYWFLJIQSM-NSJVPOEISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Dermatology (AREA)
- Steroid Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/902,190 US20160175279A1 (en) | 2013-07-02 | 2014-07-02 | Method of treating neurodegenerative disorders |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842358P | 2013-07-02 | 2013-07-02 | |
| US201461935607P | 2014-02-04 | 2014-02-04 | |
| PCT/US2014/045185 WO2015003030A1 (en) | 2013-07-02 | 2014-07-02 | Method of treating neurodegenerative disorders |
| US14/902,190 US20160175279A1 (en) | 2013-07-02 | 2014-07-02 | Method of treating neurodegenerative disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2014/045185 A-371-Of-International WO2015003030A1 (en) | 2013-07-02 | 2014-07-02 | Method of treating neurodegenerative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/624,263 Continuation US11033529B2 (en) | 2013-07-02 | 2017-06-15 | Method of treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20160175279A1 true US20160175279A1 (en) | 2016-06-23 |
Family
ID=52144185
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/902,190 Abandoned US20160175279A1 (en) | 2013-07-02 | 2014-07-02 | Method of treating neurodegenerative disorders |
| US15/624,263 Active US11033529B2 (en) | 2013-07-02 | 2017-06-15 | Method of treating neurodegenerative disorders |
| US17/228,054 Abandoned US20210322372A1 (en) | 2013-07-02 | 2021-04-12 | Method of treating neurodegenerative disorders |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/624,263 Active US11033529B2 (en) | 2013-07-02 | 2017-06-15 | Method of treating neurodegenerative disorders |
| US17/228,054 Abandoned US20210322372A1 (en) | 2013-07-02 | 2021-04-12 | Method of treating neurodegenerative disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20160175279A1 (de) |
| EP (2) | EP3016648A4 (de) |
| JP (3) | JP2016523927A (de) |
| KR (2) | KR20160026917A (de) |
| AU (3) | AU2014284304B2 (de) |
| BR (1) | BR112015032194A2 (de) |
| CA (1) | CA2916649A1 (de) |
| CL (1) | CL2015003668A1 (de) |
| HK (1) | HK1224220A1 (de) |
| IL (2) | IL242979B2 (de) |
| MX (2) | MX2015016951A (de) |
| WO (1) | WO2015003030A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL242979B2 (en) * | 2013-07-02 | 2023-03-01 | Cortice Biosciences Inc | A method for treating degenerative nerve diseases |
| US20180368472A1 (en) * | 2017-06-21 | 2018-12-27 | Altria Client Services Llc | Encapsulated ingredients for e-vaping devices and method of manufacturing thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
| US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
| US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| US8138361B2 (en) | 2005-12-28 | 2012-03-20 | The Trustees Of The University Of Pennsylvania | C-10 carbamates of taxanes |
| WO2008106621A1 (en) * | 2007-02-28 | 2008-09-04 | Tapestry Pharmaceuticals, Inc | Taxane analogs for the treatment of brain cancer |
| WO2008121476A1 (en) * | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
| US9968574B2 (en) * | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| WO2011028571A1 (en) * | 2009-09-01 | 2011-03-10 | Tapestry Pharmaceuticals, Inc. | Taxane analogues, their use, pharmaceutical compositions containing them, and processes for their preparation |
| WO2013096870A1 (en) * | 2011-12-22 | 2013-06-27 | Knopp Neurosciences Inc | Compositions and methods for treating amyotrophic lateral sclerosis |
| IL242979B2 (en) * | 2013-07-02 | 2023-03-01 | Cortice Biosciences Inc | A method for treating degenerative nerve diseases |
-
2014
- 2014-07-02 IL IL242979A patent/IL242979B2/en unknown
- 2014-07-02 JP JP2016524338A patent/JP2016523927A/ja active Pending
- 2014-07-02 IL IL296819A patent/IL296819A/en unknown
- 2014-07-02 US US14/902,190 patent/US20160175279A1/en not_active Abandoned
- 2014-07-02 MX MX2015016951A patent/MX2015016951A/es active IP Right Grant
- 2014-07-02 WO PCT/US2014/045185 patent/WO2015003030A1/en active Application Filing
- 2014-07-02 KR KR1020157037141A patent/KR20160026917A/ko not_active IP Right Cessation
- 2014-07-02 CA CA2916649A patent/CA2916649A1/en active Pending
- 2014-07-02 EP EP14819753.6A patent/EP3016648A4/de not_active Withdrawn
- 2014-07-02 EP EP19169972.7A patent/EP3536318A1/de not_active Withdrawn
- 2014-07-02 BR BR112015032194A patent/BR112015032194A2/pt not_active Application Discontinuation
- 2014-07-02 AU AU2014284304A patent/AU2014284304B2/en active Active
- 2014-07-02 KR KR1020227015596A patent/KR20220066985A/ko not_active Application Discontinuation
-
2015
- 2015-12-09 MX MX2020004106A patent/MX2020004106A/es unknown
- 2015-12-18 CL CL2015003668A patent/CL2015003668A1/es unknown
-
2016
- 2016-11-03 HK HK16112649.2A patent/HK1224220A1/zh unknown
-
2017
- 2017-06-15 US US15/624,263 patent/US11033529B2/en active Active
-
2018
- 2018-09-28 JP JP2018183806A patent/JP2018199736A/ja active Pending
-
2019
- 2019-11-28 AU AU2019271983A patent/AU2019271983B2/en active Active
-
2021
- 2021-04-12 US US17/228,054 patent/US20210322372A1/en not_active Abandoned
- 2021-07-30 JP JP2021125152A patent/JP2021167361A/ja active Pending
-
2022
- 2022-04-06 AU AU2022202313A patent/AU2022202313A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021167361A (ja) | 2021-10-21 |
| JP2016523927A (ja) | 2016-08-12 |
| KR20220066985A (ko) | 2022-05-24 |
| US20170281592A1 (en) | 2017-10-05 |
| US20210322372A1 (en) | 2021-10-21 |
| MX2015016951A (es) | 2016-08-05 |
| CA2916649A1 (en) | 2015-01-08 |
| EP3016648A1 (de) | 2016-05-11 |
| EP3016648A4 (de) | 2017-02-22 |
| IL242979B (en) | 2022-11-01 |
| US11033529B2 (en) | 2021-06-15 |
| AU2014284304B2 (en) | 2019-10-03 |
| EP3536318A1 (de) | 2019-09-11 |
| JP2018199736A (ja) | 2018-12-20 |
| IL296819A (en) | 2022-11-01 |
| IL242979A (de) | 2016-01-31 |
| MX2020004106A (es) | 2020-07-24 |
| IL242979B2 (en) | 2023-03-01 |
| HK1224220A1 (zh) | 2017-08-18 |
| AU2019271983A1 (en) | 2019-12-19 |
| AU2019271983B2 (en) | 2022-01-06 |
| AU2022202313A1 (en) | 2022-04-28 |
| AU2014284304A1 (en) | 2016-01-21 |
| CL2015003668A1 (es) | 2016-08-12 |
| WO2015003030A1 (en) | 2015-01-08 |
| KR20160026917A (ko) | 2016-03-09 |
| BR112015032194A2 (pt) | 2017-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109922800B (zh) | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 | |
| AU2022202313A1 (en) | Method of treating neurodegenerative disorders | |
| KR20110071064A (ko) | (ｒ)-프라미펙솔을 사용하는 조성물 및 방법 | |
| US11819481B2 (en) | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | |
| JP2014520856A (ja) | 併用ａｌｓ療法 | |
| US11160809B2 (en) | NK1-antagonist combination and method for treating synucleinopathies | |
| JPH08504203A (ja) | パーキンソン病およびその進行を治療する薬剤の製造のためのイダゾキサンおよびその誘導体の使用 | |
| ES2199541T3 (es) | Aplicacion del 2-amino-6-trifluorometoxi-benzotiazol para la prevencion o el tratamiento de disfunciones del cerebelo. | |
| US20240018231A1 (en) | Intranasal immunotherapt for the treatment of alzheimer's disease | |
| FR2915100A1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
| Mucke | Drug Repurposing Patent Applications January–March 2019 | |
| JP2023501217A (ja) | Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤 | |
| CN115867285A (zh) | Tau蛋白病的剂量治疗 | |
| JP2014047191A (ja) | 抗神経変性疾患剤 | |
| MX2014000455A (es) | Terapia de combinacion para esclerosis lateral amiotrofica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: CORTICE BIOSCIENCES, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEISER, MICHAEL;STEIN, JASON;PICKER, DONALD;SIGNING DATES FROM 20151202 TO 20151204;REEL/FRAME:038084/0349 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |